Safety cannot be claimed because the trial was statistically deficient! You claim no comment can be made on efficacy because the trial was underpowered and in the next breath you claim the same trial proved the compound was safe. The cohort was insufficient because the trial was badly designed. And you think the punters don't understand.
- Forums
- ASX - By Stock
- Ann: Admedus Releases Results of HSV-2 Phase IIa Study
Safety cannot be claimed because the trial was statistically...
-
- There are more pages in this discussion • 249 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M |
Open | High | Low | Value | Volume |
$18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 109 | $18.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.10 | 700 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 109 | 18.000 |
1 | 25 | 17.800 |
1 | 48 | 17.750 |
1 | 220 | 17.700 |
1 | 26 | 17.650 |
Price($) | Vol. | No. |
---|---|---|
18.100 | 700 | 1 |
18.300 | 150 | 1 |
18.500 | 43 | 1 |
18.690 | 550 | 1 |
18.750 | 143 | 1 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |